Rydapt Capsules — Midostaurin 25 mg (112 Caps) Novartis
Rydapt 25 mg (Midostaurin) is an original targeted anti-cancer medication. It acts as a multikinase inhibitor, specifically blocking the FLT3 receptor as well as other kinases (such as KIT and PDGFR). By inhibiting these enzymes, Rydapt disrupts the signals that promote the uncontrolled growth and division of malignant cells, leading to their death.
Manufacturer: Novartis. 🇹🇷 Note: This specific medication holds official Turkish registration and is packaged for the domestic market of Turkey. This ensures you are receiving a strictly regulated, authentic product from the original Swiss pharmaceutical manufacturer.
Key Features:
- ✅ Targeted Action: Specifically designed for tumors with defined genetic mutations (such as FLT3 or D816V).
- ✅ High Efficacy: Significantly improves overall survival rates when combined with standard chemotherapy regimens.
- ✅ Original Brand: The patented, original molecule developed by Novartis.
Prescribed by a hematologist-oncologist following genetic mutation testing. Indications include:
- 🔹 Acute Myeloid Leukemia (AML): For adult patients with newly diagnosed FLT3-mutated AML (used in combination with standard cytarabine and daunorubicin/idarubicin induction and cytarabine consolidation chemotherapy).
- 🔹 Systemic Mastocytosis: As a monotherapy for adults with Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN), or Mast Cell Leukemia (MCL).
Sales Unit: Multipack carton containing 112 soft capsules/tablets (4 inner packs of 28 units each). Strength: 25 mg per unit.
⚠️ APPLICATION INSTRUCTIONS:
- Dosage: Strictly individualized by the doctor. For AML, the standard dose is usually 50 mg (2 capsules) twice daily. For Mastocytosis, it is 100 mg (4 capsules) twice daily.
- Administration: Take twice a day at roughly 12-hour intervals. Must be taken with food and swallowed whole with a glass of water. Do not open, crush, or chew the capsules.
- ✋ Missed Dose: If a dose is missed or if vomiting occurs after taking a dose, do not take an extra dose. Take the next scheduled dose at the usual time.
- ⛔ Drug Interactions: Co-administration with strong CYP3A4 inducers (e.g., rifampicin, St. John's wort, carbamazepine) is strictly contraindicated as it significantly decreases the effectiveness of Rydapt.
- Hypersensitivity to midostaurin or any of the excipients.
- Pregnancy and breastfeeding (highly teratogenic; effective contraception is mandatory during and after treatment).
- Children and adolescents under 18 years of age.
Treatment requires rigorous medical supervision, including regular blood tests and ECGs. Potential side effects include:
- 🩸 Blood Counts: Febrile neutropenia (low white blood cells accompanied by fever), petechiae (small red/purple spots on the skin).
- 🤢 Gastrointestinal: Nausea, vomiting (very common; prophylactic anti-nausea medication is often prescribed), diarrhea.
- 🫀 Cardiac: Prolongation of the QT interval (requires routine ECG monitoring).
- 💤 General: Headache, severe fatigue, musculoskeletal pain.
- 🫁 Respiratory: Shortness of breath, increased risk of pulmonary infections.
What Customers Say
No reviews yet
Your review can be the first!